Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans.

ABSTRACT: Lipid nanoparticle mRNA vaccines are an exciting but emerging technology used in humans. There is limited understanding of the factors that influence their biodistribution and immunogenicity. Antibodies to poly(ethylene glycol) (PEG), which is on the surface of the lipid nanoparticle, are detectable in humans and boosted by human mRNA vaccination. We hypothesized that PEG-specific antibodies could increase the clearance of mRNA vaccines. To test this, we developed methods to quantify both the vaccine mRNA and ionizable lipid in frequent serial blood samples from 19 subjects receiving Moderna SPIKEVAX mRNA booster immunization. Both the vaccine mRNA and ionizable lipid peaked in blood 1-2 days post vaccination (median peak level 0.19 and 3.22 ng mL^-1, respectively). The vaccine m

SUBMITTER: Kent SJ 

PROVIDER: S-EPMC11447892 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature